Charcot-marie-tooth Disease, Demyelinating, Type 1a; Cmt1a
Description
For a general phenotypic description and a discussion of genetic heterogeneity of Charcot-Marie-Tooth disease type 1, see CMT1B (OMIM ).CMT1A is the most common form of CMT. The average age of onset of clinical symptoms is 12.2 +/- 7.3 years. Slow nerve conduction velocity (NCV) less than 38 m/s is highly diagnostic and is a 100% penetrant phenotype independent of age ({36,39:Lupski et al., 1991, 1992}).
Genes related to Charcot-marie-tooth Disease, Demyelinating, Type 1a; Cmt1a
- PMP22
Clinical Features
Top most frequent phenotypes and symptoms related to Charcot-marie-tooth Disease, Demyelinating, Type 1a; Cmt1a
- Global developmental delay
- Hearing impairment
- Muscle weakness
- Motor delay
- Peripheral neuropathy
- Skeletal muscle atrophy
- Areflexia
- Hyporeflexia
- Pes cavus
- Kyphoscoliosis
And another 35 symptoms. If you need more information about this disease we can help you.
Incidence and onset information
— Currently we don't have prevalence information about this disease (Not enough data available about incidence and published cases.)— No data available about the known clinical features onset.
Alternative names
Charcot-marie-tooth Disease, Demyelinating, Type 1a; Cmt1a Is also known as hereditary motor and sensory neuropathy ia, hmsn ia, charcot-marie-tooth neuropathy, type 1a, hmsn1a, charcot-marie-tooth disease, autosomal dominant, with focally folded myelin sheaths, type 1a.
Researches and researchers
Currently, we don't have any information about doctors, researches or researchers related to this disease. Please contact us if you would like to appear here.Charcot-marie-tooth Disease, Demyelinating, Type 1a; Cmt1a Recommended genes panels
Panel Name, Specifity and genes Tested/covered |
---|
CMT Advanced Evaluation - Dominant.
By Athena Diagnostics Inc (United States).
YARS, LITAF, MFN2, TRPV4, DNM2, HSPB8, EGR2, GARS, HSPB1, MPZ, NEFL, PMP22, RAB7A
Specificity
8 %
Genes
100 % |
CMT Advanced Evaluation - Dominant, Demyelinating.
By Athena Diagnostics Inc (United States).
YARS, LITAF, DNM2, EGR2, MPZ, PMP22
Specificity
17 %
Genes
100 % |
CMT Advanced Evaluation - Comprehensive.
By Athena Diagnostics Inc (United States).
YARS, PRX, GDAP1, LITAF, FIG4, MFN2, TRPV4, FGD4, SBF2, SH3TC2, DNM2, HSPB8, EGR2, GARS, GJB1, HSPB1, LMNA, MPZ, MTMR2, NDRG1 , (...)
View the complete list with 3 more genes
Specificity
5 %
Genes
100 % |
CMT Advanced Evaluation - Demyelinating.
By Athena Diagnostics Inc (United States).
YARS, PRX, GDAP1, LITAF, FIG4, FGD4, SBF2, SH3TC2, DNM2, EGR2, GJB1, MPZ, MTMR2, NDRG1, PMP22
Specificity
7 %
Genes
100 % |
Complete HNPP Evaluation.
By Athena Diagnostics Inc (United States).
PMP22
Specificity
100 %
Genes
100 % |
PMP22 Duplication/Deletion DNA Test.
By Athena Diagnostics Inc (United States).
PMP22
Specificity
100 %
Genes
100 % |
PMP22 DNA Sequencing Test.
By Athena Diagnostics Inc (United States).
PMP22
Specificity
100 %
Genes
100 % |
Entrapment Neuropathy Evaluation.
By Athena Diagnostics Inc (United States).
TTR, PMP22
Specificity
50 %
Genes
100 % |
You can get up to 117 more panels with our dedicated tool
Learn moreSources and references
You can check the following sources for additional information.
OMIM Rare Disease Symptoms CheckerIf you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like EHLERS-DANLOS SYNDROME, TYPE VII, AUTOSOMAL DOMINANT EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 36; EIEE36 JUNCTIONAL EPIDERMOLYSIS BULLOSA INVERSA